Literature DB >> 9510422

Altered guanosine and guanine concentrations in rabbit striatum following increased dopamine turnover.

D A Loeffler1, P A LeWitt, P L Juneau, D M Camp, A J DeMaggio, P Milbury, W R Matson, M P Rathbone.   

Abstract

The significance of guanine nucleotides and nucleosides in neurodegenerative disorders is suggested by recent reports that these molecules enhance neurite branching and astrocyte proliferation. The objective of this study was to investigate the influence of increased dopamine metabolism, produced by 5-day treatment of rabbits with reserpine (2 mg/kg) or levodopa (LD) (50 mg/kg), on striatal concentrations of guanosine, guanine, and their metabolites. Reserpine treatment decreased striatal guanosine by 41% and increased guanine by 50%, while LD decreased guanosine by 48% (all p < 0.01 vs. vehicle-treated controls). LD also increased guanine by 22% (not statistically significant). Xanthine and uric acid concentrations were unchanged. Because of the neurotrophic properties of guanosine and guanine, changes in striatal concentrations of these purines secondary to increased dopamine (DA) turnover may have relevance for survival of remaining dopaminergic neurons in Parkinson's disease (PD).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9510422     DOI: 10.1016/s0361-9230(97)00367-5

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  6 in total

1.  The hydrolysis of striatal adenine- and guanine-based purines in a 6-hydroxydopamine rat model of Parkinson's disease.

Authors:  Jean Pierre Oses; Cristiane Batassini; Daniela Pochmann; Ana Elisa Böhmer; Fernanda Cenci Vuaden; Roberta Bristot Silvestrin; Alcyr Oliveira; Carla Denise Bonan; Maurício Reis Bogo; Diogo Onofre Souza; Luis Valmor Cruz Portela; João José de Freitas Sarkis; Tadeu Mello e Souza
Journal:  Neurochem Res       Date:  2010-11-04       Impact factor: 3.996

2.  CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease.

Authors:  Peter LeWitt; Lonni Schultz; Peggy Auinger; Mei Lu
Journal:  Brain Res       Date:  2011-07-01       Impact factor: 3.252

3.  Metabolomic biomarkers as strong correlates of Parkinson disease progression.

Authors:  Peter A LeWitt; Jia Li; Mei Lu; Lining Guo; Peggy Auinger
Journal:  Neurology       Date:  2017-02-08       Impact factor: 9.910

4.  Opioid use affects antioxidant activity and purine metabolism: preliminary results.

Authors:  Paolo Mannelli; Ashwin Patkar; Steve Rozen; Wayne Matson; Ranga Krishnan; Rima Kaddurah-Daouk
Journal:  Hum Psychopharmacol       Date:  2009-12       Impact factor: 1.672

5.  Antiparkinsonian Efficacy of Guanosine in Rodent Models of Movement Disorder.

Authors:  Caio M Massari; Marc López-Cano; Fabiana Núñez; Víctor Fernández-Dueñas; Carla I Tasca; Francisco Ciruela
Journal:  Front Pharmacol       Date:  2017-10-04       Impact factor: 5.810

6.  Guanosine reduces apoptosis and inflammation associated with restoration of function in rats with acute spinal cord injury.

Authors:  Shucui Jiang; Farid Bendjelloul; Patrizia Ballerini; Iolanda D'Alimonte; Elenora Nargi; Cai Jiang; Xinjie Huang; Michel P Rathbone
Journal:  Purinergic Signal       Date:  2007-09-25       Impact factor: 3.765

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.